Clinical Trial Detail

NCT ID NCT02186249
Title Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Anti-CTLA-4 Treatment-Naïve Subjects With Unresectable or Metastatic Melanoma (CheckMate 218)
Recruitment No longer available
Gender both
Phase Phase III
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

melanoma

Therapies

Ipilimumab + Nivolumab

Age Groups: adult

No variant requirements are available.